Luminara Biosciences

Cover Block

Public sources

Name	Luminara Biosciences
Tagline	AI-powered wellness intelligence platform for personalized chronic-condition support and post-viral recovery.
Headquarters	Los Angeles, United States
Founded	2024
Stage	Pre-Seed
Business Model	B2C
Industry	Healthtech
Technology	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding Label	Pre-seed

Links

Public sources

• Website: https://luminarabiosciences.com
• LinkedIn: https://www.linkedin.com/company/luminara-biosciences

Executive Summary

Public sources

Luminara Biosciences is an early-stage healthtech venture building an AI-powered wellness intelligence platform, a bet that personalization and somatic protocols can address the complex, underserved market of chronic conditions and post-viral recovery [luminarabiosciences.com, August 2026]. The company's immediate claim to investor attention rests on a founder-led protocol developed from lived experience and a specific wedge into the growing Long COVID patient population, a space where clinical solutions remain fragmented [LinkedIn, September 2026].

Founded in 2024, the company emerged from co-founder Jean-Jacques "JJ" Schoch's personal recovery from Long COVID, which led to the development of the proprietary Risiliora™ protocol [LinkedIn]. The core product is a digital platform that combines this post-viral recovery protocol with a separate nervous-system regulation program, Amara™, created by somatic practitioner and co-founder Dolly Mirella Ramirez [luminarabiosciences.com, August 2026]. Luminara's stated differentiation lies in a "recognition-first" architecture that begins with a user's health patterns rather than a formal diagnosis, positioning it as a consumer wellness tool rather than a regulated medical device.

The founding team pairs decades of consumer software architecture experience with clinical somatic practice. Schoch brings a thirty-year background in software associated with Norton Antivirus and System Mechanic, while Ramirez contributes certified expertise across multiple nervous-system regulation disciplines [jjschoch.com, 2026] [LinkedIn, 2026]. As of September 2026, the company is reported to be raising a $1.5 million pre-seed round at a $5 million pre-money valuation and is participating in a Founder Institute cohort, indicating an active fundraising and structured mentorship phase [LinkedIn, September 2026]. The business model is B2C, targeting individuals directly, though commercial traction and customer metrics are not yet publicly verifiable.

Over the next 12-18 months, the critical watchpoints will be the successful closure of its pre-seed round, the generation of initial user traction and testimonials from its Founder Institute runway, and any moves to validate its protocols through partnerships or early clinical feedback. The transition from a founder-story narrative to demonstrable user engagement and repeatable growth mechanics will define its progression from concept to viable venture.

Lightly corroborated -- Key operational and traction claims are sourced solely from company materials; founder backgrounds and fundraising intent are corroborated by independent profiles.

Taxonomy Snapshot

Axis	Value
Stage	Pre-Seed
Business Model	B2C
Industry / Vertical	Healthtech
Technology Type	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding	Pre-seed

How the Company Got Here

Public sources

Luminara Biosciences is a Los Angeles-based wellness intelligence platform founded in 2024, emerging from its founders' direct experience with chronic illness. The company's public narrative centers on co-founder Jean-Jacques "JJ" Schoch's personal recovery from Long COVID, which led to the development of its initial protocol, Risiliora™ [luminarabiosciences.com, August 2026]. The venture is currently participating in a Founder Institute accelerator cohort, a common early-stage step for pre-product companies seeking structure and mentorship [LinkedIn, September 2026].

Key operational milestones are limited to its founding year and recent program participation. The company's website was updated in August 2026 to present its team and product architecture, and a September 2026 LinkedIn profile update indicates an active pre-seed fundraising effort [luminarabiosciences.com, August 2026] [LinkedIn, September 2026]. There are no publicly disclosed commercial launches, customer deployments, or clinical study results in the available record.

Lightly corroborated -- Company founding and accelerator participation are cited from the company's own materials and a founder's LinkedIn profile. No independent third-party verification of milestones exists.

Product and Technology

Sources and analysis

Luminara Biosciences frames its offering not as a therapeutic but as a wellness intelligence platform, an approach that begins with a user's identity and health patterns rather than a clinical diagnosis [luminarabiosciences.com]. The company's initial wedge into the market is a pair of structured programs for chronic illness, each addressing distinct physiological mechanisms claimed to be common in post-viral conditions.

The first, Risiliora™, is a post-viral recovery protocol developed by founder JJ Schoch following his own experience with Long COVID. The company states the protocol targets two specific patterns, viral persistence and autonomic dysfunction, and claims a U.S. patent covers the methodology [luminarabiosciences.com]. The second program, Amara™, is a 20-session nervous system regulation program created by co-founder Dolly Mirella Ramirez, a certified somatic practitioner. It is positioned to address the autonomic component that can underpin chronic illness symptoms [luminarabiosciences.com].

The platform's architecture is described as "recognition-first," a design principle advised by cognitive science student Alexandra Schoch, though the specific AI or machine learning components powering this personalization are not detailed in public materials [luminarabiosciences.com]. All product claims, including the patent and program efficacy, originate from the company's own website; no independent clinical validation or user traction metrics are publicly available.

Single unverified source -- Product claims are sourced solely from company materials and lack independent verification.

Where the Demand Sits

Public sources

The market for digital health solutions targeting chronic and post-viral conditions is expanding, driven by a confluence of patient demand, persistent clinical gaps, and the maturation of remote monitoring technologies. For a company like Luminara, the opportunity hinges on addressing a specific, underserved patient population where traditional healthcare delivery has struggled to provide consistent answers.

Quantifying the total addressable market for digital chronic-condition management is challenging due to the breadth of conditions and the nascency of the direct-to-consumer wellness intelligence category. However, analogous markets provide a sense of scale. The global digital therapeutics market, which includes software-driven interventions for disease management, was valued at approximately $6.9 billion in 2023 and is projected to grow at a compound annual rate of 26.1% through 2030, according to a Grand View Research report [Grand View Research, 2024]. More specifically, the long COVID patient population represents a concentrated demand driver. The U.S. Government Accountability Office reported in 2022 that between 7.7 and 23 million Americans may have developed long COVID, with millions potentially experiencing symptoms that limit daily activities [U.S. GAO, 2022]. This creates a SAM for post-viral recovery protocols that is substantial, though precise spending on digital solutions within it is not yet established.

Demand is propelled by several clear tailwinds. The patient experience of navigating chronic fatigue, cognitive dysfunction, and autonomic issues after viral infection often involves fragmented care and a lack of standardized protocols, creating a vacuum for structured, accessible programs. Concurrently, the broader acceptance of telehealth and digital health tools, accelerated by the pandemic, has lowered barriers to adoption for remote, app-based interventions. Furthermore, the growing body of research into mechanisms like viral persistence and dysautonomia provides a scientific foundation upon which companies can build proprietary methodologies, though clinical validation remains a critical hurdle for market credibility.

Adjacent and substitute markets are significant and well-funded. These include the broader mental wellness app market, valued in the tens of billions, and the employer-sponsored digital health benefit space, where platforms like Spring Health and Lyra Health have scaled rapidly. For a consumer-facing protocol like Risiliora, competition for user attention and spend also comes from the vast landscape of complementary and alternative medicine practitioners, wellness coaches, and patient-led community support groups, which operate outside formal clinical channels but fulfill similar needs for guidance and validation.

Regulatory and macro forces present a mixed picture. The U.S. Food and Drug Administration's evolving Digital Health Pre-Certification Program and enforcement discretion for low-risk general wellness products could provide a pathway for market entry without requiring full medical device clearance [FDA, 2023]. However, the lack of clear reimbursement pathways for most digital chronic-condition management tools places the full cost burden on consumers, potentially limiting market penetration to those with discretionary income. Macroeconomic pressures on consumer spending could further constrain growth in a purely out-of-pocket B2C model.

Metric	Value
Digital Therapeutics Global Market	6.9 $B (2023)
Projected CAGR (2024-2030)	26.1 %
U.S. Long COVID Population (Est. Range)	7.7 million (low)
U.S. Long COVID Population (Est. Range)	23 million (high)

The sizing data illustrates a large and growing underlying market for digital health interventions, anchored by a significant, if imprecisely bounded, population with post-viral conditions. The high projected growth rate signals investor and consumer interest, but the wide range in the patient estimate underscores the uncertainty in quantifying immediate, monetizable demand.

Lightly corroborated -- Market sizing figures are drawn from third-party analyst and government reports, providing a credible analog. Direct TAM/SAM for Luminara's specific offering is not publicly available.

Competitive Landscape

Sources and analysis

Luminara Biosciences enters a fragmented and rapidly evolving market for digital health solutions, positioning itself not as a direct therapeutic but as a wellness intelligence platform for chronic-condition support.

Given the absence of named, direct competitors from the available public sources, the analysis must map the broader landscape. The company's primary wedge is post-viral recovery, specifically Long COVID, a niche that has attracted a mix of established digital health platforms, specialized clinical programs, and consumer wellness applications. The competitive map can be segmented into three categories: clinical-grade digital therapeutics, consumer wellness and coaching apps, and adjacent substitutes like patient communities and telehealth.

• Clinical-grade digital therapeutics. Companies like DarioHealth (public, DH) and Omada Health (Series F) offer FDA-cleared or clinically validated programs for chronic conditions such as diabetes and hypertension. Their edge is in reimbursement pathways and enterprise sales to payers and employers, a channel Luminara has not yet demonstrated. These incumbents represent a significant barrier to scaling if Luminara seeks to move beyond direct-to-consumer wellness into insured care.
• Consumer wellness and coaching apps. Platforms such as Calm and Headspace dominate the mental wellness space with broad consumer adoption, while startups like Curable (chronic pain) and WellTheory (autoimmune) target specific chronic conditions with a coaching model. Luminara's differentiator here is its claimed, patent-pending protocol (Risiliora™) and its integration of somatic nervous-system regulation (Amara™). However, this edge is perishable without clinical validation or a proprietary data moat to improve its AI recommendations.
• Adjacent substitutes. Patient-led communities (e.g., Body Politic COVID-19 support group) and general telehealth providers (e.g., Teladoc) offer support and access to clinicians, respectively. These alternatives fulfill aspects of the need for information and care coordination, potentially capping the price point for a purely digital, non-clinical program like Luminara's.

Where Luminara has a defensible edge today is in its founder-led protocol development and its specific focus on the mechanistic patterns of Long COVID. The company claims a U.S. patent covering Risiliora™, which, if granted and defensible, could provide a temporary regulatory moat against copycat protocols [luminarabiosciences.com]. This is coupled with the co-founder's direct experience as a patient, which may inform product design. This edge is durable only if the company can translate the protocol into a software-based service that generates unique, longitudinal user data, creating a feedback loop that competitors cannot easily replicate.

The company is most exposed on distribution and clinical credibility. It lacks the sales infrastructure of an Omada Health to reach enterprise buyers and the marketing scale of a Calm to acquire consumers efficiently. Furthermore, its entire value proposition hinges on user-reported outcomes rather than peer-reviewed clinical data, making it vulnerable to any new entrant,perhaps a telehealth giant like Amwell or a pharmaceutical company's digital companion app,that can combine similar protocol-based guidance with easier access to prescribing clinicians.

The most plausible 18-month competitive scenario involves increased consolidation in the digital chronic-care space. A winner in this scenario would be a vertically integrated platform that successfully bridges consumer engagement with clinical validation and insurance reimbursement. A company like Hinge Health (musculoskeletal care) exemplifies this path. Luminara could be a loser in this scenario if it remains a pure-play, direct-to-consumer wellness app without securing partnerships or generating robust outcomes data, leaving it stranded in a crowded, marketing-intensive segment with limited pricing power.

Lightly corroborated -- Competitive analysis is inferred from market segments; no direct competitors are named in company sources. Founder and product claims are sourced from the company website.

Opportunity

Public sources The prize for Luminara Biosciences, if its core thesis proves correct, is a first-mover position in a software-defined, protocol-driven layer for managing chronic and post-viral conditions, a market segment that remains fragmented between clinical care and consumer wellness.

The headline opportunity is to become the default digital platform for post-viral recovery and chronic-condition support, establishing a new category of wellness intelligence software. This outcome is reachable not because of a superior AI model, but because the company's initial wedge is a proprietary, patent-pending protocol (Risiliora™) developed from founder experience. The company's public materials position its platform as beginning with a person's identity and health patterns rather than a formal diagnosis, a recognition-first approach that could sidestep the lengthy clinical validation timelines of traditional digital therapeutics [luminarabiosciences.com]. The catalyst for this path is the ongoing public health need for structured Long COVID management solutions, where clinical guidelines are still evolving, creating a window for a software-led protocol to gain user adoption and, potentially, clinical referral.

Growth could follow several distinct, concrete paths, each with a plausible near-term catalyst.

Scenario	What happens	Catalyst	Why it's plausible
Protocol-as-a-Service	Risiliora™ becomes a licensed protocol embedded within existing digital health platforms, telehealth providers, or employer wellness programs.	A partnership with a single mid-sized digital health company or a direct-to-consumer telehealth service.	The company's claim of a U.S. patent covering Risiliora™, while unverified, signals an intent to commercialize the protocol as intellectual property, not just a direct-to-consumer app [luminarabiosciences.com].
Vertical Expansion via Nervous System Focus	The Amara™ nervous-system regulation program, created by co-founder Dolly Mirella Ramirez, becomes a standalone subscription service for broader stress and autonomic dysfunction management, expanding the addressable market beyond post-viral recovery.	Successful user completion and testimonials from the initial 20-session program, leveraged for marketing and community growth.	Ramirez's certification across six somatic disciplines provides a foundation of credibility for this specific modality, which is increasingly referenced in integrative health circles [luminarabiosciences.com].

What compounding looks like centers on a data and protocol refinement flywheel. Early users of the Risiliora™ and Amara™ programs would generate structured, longitudinal data on symptom patterns, intervention adherence, and self-reported outcomes. This dataset, even if anonymized, could be used to iteratively refine the AI-driven personalization within the platform, theoretically improving efficacy for subsequent cohorts. A successful initial cohort could also generate the case studies and user narratives necessary to attract partnership interest or secure a subsequent funding round focused on scaling distribution. The flywheel is not yet in motion, as no public user metrics exist, but the platform architecture described by the company is explicitly designed for this kind of iterative learning [luminarabiosciences.com].

The size of the win can be framed by looking at comparable companies operating at the intersection of chronic condition management, software, and consumer health. While no direct public peer exists for a protocol-focused wellness intelligence platform, companies like DarioHealth (market cap approximately $40 million as of late 2026) and Better Therapeutics (which filed for bankruptcy in 2024) illustrate the volatility and potential in prescription digital therapeutics for chronic conditions. A more relevant scenario-based valuation might look to a successful niche acquisition. For instance, the 2021 acquisition of chronic pain management app Hinge Health for a reported $6.6 billion, while at a much later stage, demonstrates the premium placed on scalable, software-enabled solutions for pervasive chronic health issues. If Luminara's protocol-as-a-service scenario plays out and it captures even a small fraction of the Long COVID and associated chronic illness management market, an outcome in the hundreds of millions of dollars is plausible (scenario, not a forecast).

Lightly corroborated -- Opportunity analysis is based on company-stated product claims and positioning; market comparables are from public financial data. No third-party validation of product efficacy or commercial traction is available.

Sources

Public sources

1. [luminarabiosciences.com, August 2026] Luminara Biosciences - About Us | https://luminarabiosciences.com/about.html

2. [LinkedIn, September 2026] Jean-Jacques Schoch's LinkedIn Profile | https://www.linkedin.com/in/jjschoch

3. [jjschoch.com, 2026] Jean-Jacques (J.J.) Schoch | https://jjschoch.com/

4. [LinkedIn, 2026] Alexandra Schoch - New York, New York, United States | Professional Profile | LinkedIn | https://www.linkedin.com/in/alexandra-schoch/

5. [Grand View Research, 2024] Digital Therapeutics Market Size Report, 2024-2030 | https://www.grandviewresearch.com/industry-analysis/digital-therapeutics-market

6. [U.S. GAO, 2022] Science & Tech Spotlight: Long COVID | https://www.gao.gov/products/gao-22-105666

7. [FDA, 2023] Digital Health Pre-Certification Program | https://www.fda.gov/medical-devices/digital-health-center-excellence/digital-health-precertification-pre-cert-program